We propose to establish a multidisciplinary team of epidemiologists, statisticians, basic scientists and clinician scientists to promote and pursue thorough identification and characterization of genomic loci associated with prostate cancer. ELLIPSE (ELucidating Loci Involved in Prostate cancer SuscEptibility) is a translational grant comprised of three highly integrated projects. Project 1 aims to take advantage of existing and shortly to be completed GWAS of prostate cancer in European, African American, Latino and Japanese populations to discover novel risk loci, and to rigorously replicate these associations in large existing consortia of prostate cases and controls (PRACTICAL, BPC3, and MADCaP). A major focus of this expanded effort is to identify loci that may selectively be associated with advanced disease and variants that contribute to ethnic difference in disease risk. Selective fine mapping of risk loci will also be performed to comprehensively characterize the relevant allelic locus, utilizing all available data on common variants from Hapmap, selective sequencing efforts, and from the 1000 Genome Project. Project 2 is focused on understanding the gene(s) that the non-protein coding risk variants are acting through. Two hypotheses will be systematically explored using a wide variety of established and emerging techniques: the risk loci harbor as yet undetected transcripts (either coding or non-coding) and the risk loci are regulatory elements. Finally, in Project 3 we propose to investigate the potential of this new knowledge on the genetic basis of prostate cancer susceptibility to enhance risk assessment, through gene-gene and gene-environment interactions, and importantly, to provide the potential for novel clinical practices through impacts on cancer diagnosis and treatment, or newer cancer prevention strategies. The overarching goal is to discover the pathways that drive prostate cancer pathogenesis and to assess their role in clinical decision making.
The discovery of novel risk alleles for prostate cancer will provide new insights into biological pathways that are important in the development of prostate cancer, particularly aggressive disease. This insight into prostate cancer biology will disclose novel targets for chemopreventive and therapeutic interventions and may reveal approaches to primary prevention.
|Han, Ying; Signorello, Lisa B; Strom, Sara S et al. (2015) Generalizability of established prostate cancer risk variants in men of African ancestry. Int J Cancer 136:1210-7|
|Agarwal, D; Pineda, S; Michailidou, K et al. (2014) FGF receptor genes and breast cancer susceptibility: results from the Breast Cancer Association Consortium. Br J Cancer 110:1088-100|
|Al Olama, Ali Amin; Kote-Jarai, Zsofia; Berndt, Sonja I et al. (2014) A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. Nat Genet 46:1103-9|
|Lindström, Sara; Thompson, Deborah J; Paterson, Andrew D et al. (2014) Genome-wide association study identifies multiple loci associated with both mammographic density and breast cancer risk. Nat Commun 5:5303|
|Pooley, Karen A; McGuffog, Lesley; Barrowdale, Daniel et al. (2014) Lymphocyte telomere length is long in BRCA1 and BRCA2 mutation carriers regardless of cancer-affected status. Cancer Epidemiol Biomarkers Prev 23:1018-24|
|Hazelett, Dennis J; Rhie, Suhn Kyong; Gaddis, Malaina et al. (2014) Comprehensive functional annotation of 77 prostate cancer risk loci. PLoS Genet 10:e1004102|
|Andreassen, Ole A; Zuber, Verena; Thompson, Wesley K et al. (2014) Shared common variants in prostate cancer and blood lipids. Int J Epidemiol 43:1205-14|
|Eeles, Rosalind; Goh, Chee; Castro, Elena et al. (2014) The genetic epidemiology of prostate cancer and its clinical implications. Nat Rev Urol 11:18-31|
|Milne, Roger L; Burwinkel, Barbara; Michailidou, Kyriaki et al. (2014) Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium. Hum Mol Genet 23:6096-111|
|Li, Jingmei; Lindström, Linda S; Foo, Jia N et al. (2014) 2q36.3 is associated with prognosis for oestrogen receptor-negative breast cancer patients treated with chemotherapy. Nat Commun 5:4051|
Showing the most recent 10 out of 40 publications